Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.
We report the case of a 58-year-old man with multiple myeloma stage III A who received tandem autologous stem cell transplantation after induction by two courses of VAD and three cycles of bortezomib-dexamethasone, due to progression under chemotherapy. The second transplantation was complicated by severe hepatic veno-occlusive disease (HVOD). The patient received defibrotide with total recovery. The occurence of HVOD after conditioning by melphalan is uncommon and the role of bortezomib was questioned.
Labidi
Sana Intidhar
SI
Department of Medical Oncology, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France. LABIDI@lyon.fnclcc.fr.
Sebban
Catherine
C
Department of Medical Oncology, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France.
Ghesquières
Hervé
H
Department of Medical Oncology, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France.
Nicolas
Emmanuele Virelizier
EV
Department of Medical Oncology, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France.
Biron
Pierre
P
Department of Medical Oncology, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy; D019653:Myeloablative Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014182:Transplantation, Autologous
D001897:Boronic Acids; D019653:Myeloablative Agonists; D011719:Pyrazines; D000069286:Bortezomib; D005047:Etoposide; D003907:Dexamethasone; D004317:Doxorubicin; D008558:Melphalan